Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthieu Groh

Showing results (71-80 of 116) with videos related to

Pageof 12
Sort By:
European Journal of Internal Medicine|May 15, 2015
Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) Consensus Task Force recommendations for evaluation and managementMatthieu Groh, Christian Pagnoux, Chiara Baldini, et al.
Rheumatology (Oxford, England)|June 10, 2025
Prognosis of essential mixed cryoglobulinemia and connective tissue disease-related cryoglobulinemia after rituximab-induced remissionClaire Poggi, Eric Hachulla, Alexandre Karras, et al.
Autoimmunity Reviews|December 16, 2019
Giant-cell arteritis associated with myelodysplastic syndrome: French multicenter case control study and literature reviewAnne Laure Roupie, Hubert de Boysson, Sara Thietart, et al.
Journal of Clinical Medicine|December 10, 2021
USAID Associated with Myeloid Neoplasm and VEXAS Syndrome: Two Differential Diagnoses of Suspected Adult Onset Still's Disease in Elderly PatientsMarion Delplanque, Achille Aouba, Pierre Hirsch, et al.
Nature Medicine|May 5, 2026
Author Correction: Benralizumab versus placebo for hypereosinophilic syndrome: a randomized, placebo-controlled phase 3 trialPrincess U Ogbogu, Florence Roufosse, Praveen Akuthota, et al.
Nature Medicine|March 31, 2026
Benralizumab versus placebo for hypereosinophilic syndrome: a randomized, placebo-controlled phase 3 trialPrincess U Ogbogu, Florence Roufosse, Praveen Akuthota, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 7, 2016
Anti-IgE Monoclonal Antibody (Omalizumab) in Refractory and Relapsing Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss): Data on Seventeen PatientsMarie Jachiet, Maxime Samson, Vincent Cottin, et al.
Annals of the Rheumatic Diseases|August 7, 2023
Benralizumab for eosinophilic granulomatosis with polyangiitisAdrien Cottu, Matthieu Groh, Charlene Desaintjean, et al.
The Journal of Allergy and Clinical Immunology. in Practice|September 17, 2019
Assessment of T-cell polarization on the basis of surface marker expression: Diagnosis and potential therapeutic implications in lymphocytic variant hypereosinophilic syndromeEmmanuel Ledoult, Matthieu Groh, Jean-Emmanuel Kahn, et al.
The Journal of Allergy and Clinical Immunology. in Practice|December 22, 2019
"Idiopathic Eosinophilic Vasculitis": Another Side of Hypereosinophilic Syndrome? A Comprehensive Analysis of 117 Cases in Asthma-Free PatientsGuillaume Lefèvre, Amélie Leurs, Jean-Baptiste Gibier, et al.
Pageof 12

Showing results (71-80 of 116) with videos related to

Sort By:
Pageof 12
European Journal of Internal Medicine|May 15, 2015
Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) Consensus Task Force recommendations for evaluation and managementMatthieu Groh, Christian Pagnoux, Chiara Baldini, et al.
Rheumatology (Oxford, England)|June 10, 2025
Prognosis of essential mixed cryoglobulinemia and connective tissue disease-related cryoglobulinemia after rituximab-induced remissionClaire Poggi, Eric Hachulla, Alexandre Karras, et al.
Autoimmunity Reviews|December 16, 2019
Giant-cell arteritis associated with myelodysplastic syndrome: French multicenter case control study and literature reviewAnne Laure Roupie, Hubert de Boysson, Sara Thietart, et al.
Journal of Clinical Medicine|December 10, 2021
USAID Associated with Myeloid Neoplasm and VEXAS Syndrome: Two Differential Diagnoses of Suspected Adult Onset Still's Disease in Elderly PatientsMarion Delplanque, Achille Aouba, Pierre Hirsch, et al.
Nature Medicine|May 5, 2026
Author Correction: Benralizumab versus placebo for hypereosinophilic syndrome: a randomized, placebo-controlled phase 3 trialPrincess U Ogbogu, Florence Roufosse, Praveen Akuthota, et al.
Nature Medicine|March 31, 2026
Benralizumab versus placebo for hypereosinophilic syndrome: a randomized, placebo-controlled phase 3 trialPrincess U Ogbogu, Florence Roufosse, Praveen Akuthota, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 7, 2016
Anti-IgE Monoclonal Antibody (Omalizumab) in Refractory and Relapsing Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss): Data on Seventeen PatientsMarie Jachiet, Maxime Samson, Vincent Cottin, et al.
Annals of the Rheumatic Diseases|August 7, 2023
Benralizumab for eosinophilic granulomatosis with polyangiitisAdrien Cottu, Matthieu Groh, Charlene Desaintjean, et al.
The Journal of Allergy and Clinical Immunology. in Practice|September 17, 2019
Assessment of T-cell polarization on the basis of surface marker expression: Diagnosis and potential therapeutic implications in lymphocytic variant hypereosinophilic syndromeEmmanuel Ledoult, Matthieu Groh, Jean-Emmanuel Kahn, et al.
The Journal of Allergy and Clinical Immunology. in Practice|December 22, 2019
"Idiopathic Eosinophilic Vasculitis": Another Side of Hypereosinophilic Syndrome? A Comprehensive Analysis of 117 Cases in Asthma-Free PatientsGuillaume Lefèvre, Amélie Leurs, Jean-Baptiste Gibier, et al.
Pageof 12